Clinical Trial Update: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor [Phase 1]

View source ↗

Summary

A Phase 1 study of the combination of duvelisib and venetoclax in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)
• Venclexta (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: WITHDRAWN